Market Access News | pharmaphorum

News

EU first to approve Dupixent for COPD

Chronic obstructive pulmonary disease (COPD) has seen no new therapies brought to market for around 10 years – and now there have been two in the space of a couple of weeks.

News

Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage

Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease therapy donanemab and will launch it at a cost it claims could deliver savings compared to a rival therapy fro

News

$refractory chronic gout$

Sobi starts rolling FDA filing for chronic gout drug

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to cu

News

Apellis will appeal CHMP’s rejection of pegcetacoplan

Apellis Pharma has said it will seek a re-evaluation of its marketing application for Syfovre for eye disease geographic atrophy (GA) after the EMA’s human medicines committee turned it dow

News

France agrees to fund experimental glioblastoma therapy

France has agreed to provide temporary funding to help a clinical trial of an experimental therapy for glioblastoma, a notoriously hard-to-treat form of brain cancer, to go ahead.

News

AstraZeneca files rival to Pemgarda for COVID PrEP

AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP).

EU first to approve Dupixent for COPD

Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage

Sobi starts rolling FDA filing for chronic gout drug

Apellis will appeal CHMP’s rejection of pegcetacoplan

France agrees to fund experimental glioblastoma therapy

AstraZeneca files rival to Pemgarda for COVID PrEP

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks